Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management

Join us for this live, CME-certified symposium featuring review and discussion of patient case studies and key clinical trial data by renowned clinical experts providing their perspectives on recent advances in the use of Bruton’s tyrosine kinase (BTK) inhibitors to treat mantle cell lymphoma, chronic lymphocytic leukemia, and other B-cell malignancies

You will have multiple opportunities to interact with faculty through interactive patient case scenarios and dynamic question and answer sessions.

Friday Satellite Symposium preceding the 61st ASH Annual Meeting & Exposition.


6:00 – 6:30 PM Registration and Dinner

6:30 – 6:35 PM Welcome and Introduction

6:35 – 6:45 PM Overview of the BCR Pathway and BTK in Tumor Development

6:45 – 7:05 PM Safety and Use of BTK inhibitors For The Management of B-Cell Malignancies

7:05 – 8:35 PM Practical Case Discussions: Selecting BTK inhibitor Therapy in B-Cell Malignancies

Faculty will present patient case examples with interactive audience questions, discuss the current data for each case, and facilitate panel discussions and audience questions for each case.

8:35 – 8:50 PM Overcoming BTK Inhibitor Resistance and Combination Strategies

8:50 – 9:05 PM Panel Discussion and Final Audience Question and Answer Session

9:05 – 9:20 PM Summary and Final Thoughts


Date / Time
Event Details


Program Director
Ian Flinn, MD

Director, Lymphoma Research Program
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee

Jan A. Burger, MD, PhD

Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Alexey Danilov, MD

Associate Professor of Medicine
Department of Hematology/Oncology
Knight Cancer Institute
Oregon Health and Science University
Portland, Oregon

John Pagel, MD, PhD

Chief of Hematologic Malignancies
Swedish Cancer Institute
Seattle, Washington

Goal Statement
The goal of this activity is to improve participants’ knowledge of and competence in selecting and safely integrating BTK inhibitors within the current treatment paradigm for various B-cell malignancies considering patient-specific and prognostic factors as well as appropriate dosing and strategies to manage treatment-emergent adverse events.

Target Audience
This program is intended for hematologists, hematologist-oncologists, and other clinicians involved in the management of patients with MCL, CLL, and other B-cell malignancies.

Learning Objectives

  • Evaluate differences among agents targeting BTK in terms of molecular characteristics, preclinical data, approved indications, dosing, safety profile, and efficacy
  • Plan optimal, individualized therapeutic strategies for patients with MCL, CLL/SLL, WM and other B-cell malignancies taking into consideration recent practice-changing clinical trial results
  • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, quality of life, and continuation of treatment
  • Assess ongoing clinical trials evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) to aid clinical trial enrollment and predict new options in the clinic


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.